Stockscreener 앱 받기
9.08
6.39%
-0.62
시간 외 거래:
9.05
-0.03
-0.33%
전일 마감가:
$9.70
열려 있는:
$9.68
하루 거래량:
1.78M
Relative Volume:
1.11
시가총액:
$807.76M
수익:
$71.64M
순이익/손실:
$-294.57M
주가수익비율:
-2.7121
EPS:
-3.348
순현금흐름:
$-84.46M
1주 성능:
-14.34%
1개월 성능:
-18.93%
6개월 성능:
+1.57%
1년 성능:
-10.37%
1일 변동 폭
$9.05
$9.68
1주일 범위
$9.05
$10.68
52주 변동 폭
$7.3575
$13.90
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.08 | 807.76M | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-01 | 개시 | JP Morgan | Overweight |
| 2026-04-14 | 개시 | Lake Street | Buy |
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes - GlobeNewswire
Caspian Therapeutics and Kura Oncology to host investor call By Investing.com - Investing.com
Caspian Therapeutics and Kura Oncology to Host Investor Webcast on Caspian Formation and KO-7246 Data from EASD Meeting - Quiver Quantitative
Caspian Therapeutics and Kura Oncology to Host Investor - GlobeNewswire
Kura Oncology (KURA) Stock Price, News & Analysis - Stock Titan
Kura Oncology Share PriceKURA, RNS News, Articles, Quotes, & Charts (NASDAQ:KURA) - Proactive financial news
Why Is KURA Stock Rallying 8% After-Hours? - Stocktwits
Kura Oncology Inc. Company & People | KUR - Barron's
Nine new hires get rights to buy 128,250 Kura shares, phased in over four years. - Stock Titan
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kura Oncology, Inc. : JP Morgan Initiates Cov - Moomoo
Kura Oncology, Inc. (KURA) stock price, news, quote and history - uk.finance.yahoo.com
Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kura Oncology CCO Brian Powl sells over $345k in company stock - Investing.com
Kura Oncology SVP sells $48,360 of stock - Investing.com
Kura Oncology COO Kathleen Ford sells $111,930 in company stock - Investing.com
A tax-related sale followed stock vesting: Kura Oncology (KURA) executive sold 4,607 shares. - Stock Titan
One sale covered taxes; two followed a trading plan. Kura Oncology (KURA) executive sold 32,450 shares. - Stock Titan
Return on equity % of Kura Oncology, Inc. – HAN:KUR - TradingView
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR - TradingView
Kura Oncology, Inc. Revenue Breakdown – HAN:KUR - TradingView
ETFs Investing in Kura Oncology, Inc. Stocks - TradingView
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR - TradingView
After three earlier sales, a Kura Oncology (KURA) officer proposes another share sale - Stock Titan
After selling 12,448 shares, a Kura Oncology (KURA) officer proposes selling 28,802 more. - Stock Titan
Shares valued at $74,308.56 are proposed for sale by Kura Oncology (KURA) officer Kathleen Ford. - Stock Titan
An August sale of 31,487 stock units precedes another proposed sale by Kura Oncology (KURA) officer Teresa Bair. - Stock Titan
A planned $133,940 share sale at Kura Oncology (KURA) involves officer Mollie Leoni. - Stock Titan
Shares valued at $49,571 are in a proposed sale by Kura Oncology (KURA) officer Thomas James Doyle. - Stock Titan
Two sales, two reasons: Kura Oncology (KURA) medical chief sold shares to cover taxes and under a trading plan. - Stock Titan
A stock award triggers a tax-covering share sale by Kura Oncology (KURA) COO Kathleen Ford. - Stock Titan
A tax-related sale leaves Kura Oncology (KURA) legal chief with 187,002 shares. - Stock Titan
Form 144 KURA ONCOLOGY For: 25 September By Investing.com - Investing.com Canada
Shares from a stock option exercise are proposed for sale by a Kura Oncology (KURA) officer, valued at $224,514. - Stock Titan
Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech Innovator with a 173% Potential Upside - DirectorsTalk Interviews
Kura Oncology (KURA) awards CFO 450,000 stock options - Stock Titan
Kura Oncology (KURA) CFO files initial ownership report with no trades - Stock Titan
Kura Oncology Maintains 49.2% Stake in Caspian Therapeutics Following $50M Series A Funding - Kalkine Media
Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes - insights.citeline.com
Kura assets flow to Caspian for cardiometabolic indications - BioWorld News
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - AOL.com
Kura Oncology Raises $50M for Cardiometabolic Subsidiary Caspian - minichart.com.sg
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions - Investing.com India
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - Yahoo Finance
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Appoints Jennifer Fulk as New CFO - The Globe and Mail
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus - TipRanks
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kura Oncology Inc 주식 (KURA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KATHLEEN FORD | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
3,668 |
38,917 |
0 |
| MOLLIE LEONI | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
28,802 |
305,589 |
0 |
| BRIAN POWL | Officer |
Sep 29 '26 |
Proposed Sale |
10.61 |
15,430 |
163,712 |
0 |
| Powl Brian T. | Chief Commercial Officer |
Sep 29 '26 |
Sale |
10.75 |
15,430 |
165,852 |
136,819 |
| Leoni Mollie | Chief Medical Officer |
Sep 29 '26 |
Sale |
10.75 |
28,802 |
309,567 |
141,095 |
| FORD KATHLEEN | Chief Operating Officer |
Sep 29 '26 |
Sale |
10.75 |
3,668 |
39,437 |
142,986 |
| DOYLE THOMAS JAMES | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
4,607 |
49,571 |
0 |
| FORD KATHLEEN | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
6,906 |
74,309 |
0 |
| BAIR TERESA BROPHY | Officer |
Sep 28 '26 |
Proposed Sale |
10.76 |
8,442 |
90,836 |
0 |
| Powl Brian T. | Chief Commercial Officer |
Sep 28 '26 |
Sale |
10.53 |
17,020 |
179,183 |
152,249 |
6.92%
자본화:
|
볼륨(24시간):